Base de dados : MEDLINE
Pesquisa : G12.450.050.370 [Categoria DeCS]
Referências encontradas : 3364 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 337 ir para página                         

  1 / 3364 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28961410
[Au] Autor:Mingozzi F; High KA
[Ad] Endereço:Genethon and INSERM U951, 91000 Evry, France; email: federico.mingozzi@inserm.fr.
[Ti] Título:Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape.
[So] Source:Annu Rev Virol;4(1):511-534, 2017 Sep 29.
[Is] ISSN:2327-0578
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Immune responses in gene therapy with adeno-associated virus (AAV) vectors have been the object of almost two decades of study. Although preclinical models helped to define and predict certain aspects of interactions between the vector and the host immune system, most of our current knowledge has come from clinical trials. These studies have allowed development of effective interventions for modulating immunotoxicities associated with vector administration, resulting in therapeutic advances. However, the road to full understanding and effective modulation of immune responses in gene therapy is still long; the determinants of the balance between tolerance and immunogenicity in AAV vector-mediated gene transfer are not fully understood, and effective solutions for overcoming preexisting neutralizing antibodies are still lacking. However, despite these challenges, the goal of reliably delivering effective gene-based treatments is now in sight.
[Mh] Termos MeSH primário: Anticorpos Neutralizantes/imunologia
Dependovirus/imunologia
Vetores Genéticos
Tolerância Imunológica
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/efeitos adversos
Anticorpos Neutralizantes/biossíntese
Dependovirus/genética
Técnicas de Transferência de Genes
Terapia Genética
Vetores Genéticos/efeitos adversos
Seres Humanos
Imunidade Ativa
Camundongos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antibodies, Neutralizing)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171027
[Lr] Data última revisão:
171027
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170930
[St] Status:MEDLINE
[do] DOI:10.1146/annurev-virology-101416-041936


  2 / 3364 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28683272
[Au] Autor:Neukomm LJ; Burdett TC; Seeds AM; Hampel S; Coutinho-Budd JC; Farley JE; Wong J; Karadeniz YB; Osterloh JM; Sheehan AE; Freeman MR
[Ad] Endereço:Department of Neurobiology, University of Massachusetts Medical School, Worcester, MA, USA. Electronic address: lukas.neukomm@gmail.com.
[Ti] Título:Axon Death Pathways Converge on Axundead to Promote Functional and Structural Axon Disassembly.
[So] Source:Neuron;95(1):78-91.e5, 2017 Jul 05.
[Is] ISSN:1097-4199
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Axon degeneration is a hallmark of neurodegenerative disease and neural injury. Axotomy activates an intrinsic pro-degenerative axon death signaling cascade involving loss of the NAD biosynthetic enzyme Nmnat/Nmnat2 in axons, activation of dSarm/Sarm1, and subsequent Sarm-dependent depletion of NAD . Here we identify Axundead (Axed) as a mediator of axon death. axed mutants suppress axon death in several types of axons for the lifespan of the fly and block the pro-degenerative effects of activated dSarm in vivo. Neurodegeneration induced by loss of the sole fly Nmnat ortholog is also fully blocked by axed, but not dsarm, mutants. Thus, pro-degenerative pathways activated by dSarm signaling or Nmnat elimination ultimately converge on Axed. Remarkably, severed axons morphologically preserved by axon death pathway mutations remain integrated in circuits and able to elicit complex behaviors after stimulation, indicating that blockade of axon death signaling results in long-term functional preservation of axons.
[Mh] Termos MeSH primário: Proteínas do Domínio Armadillo/genética
Axônios/metabolismo
Proteínas do Citoesqueleto/genética
Proteínas de Drosophila/genética
Nicotinamida-Nucleotídeo Adenililtransferase/genética
Degeneração Walleriana/genética
[Mh] Termos MeSH secundário: Animais
Animais Geneticamente Modificados
Proteínas do Domínio Armadillo/metabolismo
Antenas de Artrópodes/lesões
Antenas de Artrópodes/inervação
Axotomia
Comportamento Animal
Western Blotting
Linhagem Celular
Proteínas do Citoesqueleto/metabolismo
Proteínas de Drosophila/metabolismo
Drosophila melanogaster
Asseio Animal
Imunidade Ativa
NAD/metabolismo
Neurônios/metabolismo
Nicotinamida-Nucleotídeo Adenililtransferase/metabolismo
Optogenética
Degeneração Walleriana/metabolismo
Asas de Animais/lesões
Asas de Animais/inervação
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Armadillo Domain Proteins); 0 (Cytoskeletal Proteins); 0 (Drosophila Proteins); 0 (Sarm protein, Drosophila); 0 (axundead protein, Drosophila); 0U46U6E8UK (NAD); EC 2.7.7.1 (Nicotinamide-Nucleotide Adenylyltransferase)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170801
[Lr] Data última revisão:
170801
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170707
[St] Status:MEDLINE


  3 / 3364 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28498097
[Au] Autor:Dionne B; Dehority W; Brett M; Howdieshell TR
[Ad] Endereço:1 Department of Pharmacy and Health Systems Sciences, School of Pharmacy, Bouvé College of Health Sciences, Northeastern University , Boston, Massachusetts.
[Ti] Título:The Asplenic Patient: Post-Insult Immunocompetence, Infection, and Vaccination.
[So] Source:Surg Infect (Larchmt);18(5):536-544, 2017 Jul.
[Is] ISSN:1557-8674
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Splenic injury can occur through multiple mechanisms and may result in various degrees of residual immunocompetence. Functionally or anatomically asplenic patients are at higher risk for infection, particularly with encapsulated bacteria. Vaccination is recommended to prevent infection with these organisms; however, the recommendations are routinely updated, and vaccine selection and timing are complex. METHODS: Review of the pertinent English-language literature, including the recommendations of the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. RESULTS: Overwhelming post-splenectomy infection is associated with high morbidity and mortality rates. Patients requiring splenectomy for trauma-related injury appear to be at lower risk for infection than those undergoing splenectomy for a hematologic or oncologic indication. Initial vaccination is dependent on immunization history but generally should consist of the 13-valent pneumococcal conjugate, quadrivalent meningococcal conjugate, meningococcal serogroup B, and Haemophilus influenzae serotype b (Hib) vaccines. Antimicrobial prophylaxis for certain asplenic patients, such as children under the age of five y, may be indicated. CONCLUSION: Immunization remains a key measure to prevent overwhelming post-splenectomy infection. Consideration of new recommendations and indications, possible interactions, and timing remains important to including optimal response to the vaccines.
[Mh] Termos MeSH primário: Imunocompetência
Complicações Pós-Operatórias
Guias de Prática Clínica como Assunto
Esplenectomia
Vacinação
[Mh] Termos MeSH secundário: Antibioticoprofilaxia
Seres Humanos
Imunidade Ativa
Assistência Perioperatória
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171030
[Lr] Data última revisão:
171030
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170513
[St] Status:MEDLINE
[do] DOI:10.1089/sur.2016.267


  4 / 3364 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28391357
[Au] Autor:Lilleby W; Gaudernack G; Brunsvig PF; Vlatkovic L; Schulz M; Mills K; Hole KH; Inderberg EM
[Ad] Endereço:Department of Oncology and Radiotherapy, Oslo University Hospital-Radiumhospitalet, PO Box 4953, Nydalen, 0424, Oslo, Norway. Wolfgang.lilleby@ous-hf.no.
[Ti] Título:Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.
[So] Source:Cancer Immunol Immunother;66(7):891-901, 2017 Jul.
[Is] ISSN:1432-0851
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:In newly diagnosed metastatic hormone-naive prostate cancer (mPC), telomerase-based immunotherapy with the novel hTERT peptide vaccine UV1 can induce immune responses with potential clinical benefit. This phase I dose escalation study of UV1 evaluated safety, immune response, effects on prostate-specific antigen (PSA) levels, and preliminary clinical outcome. Twenty-two patients with newly diagnosed metastatic hormone-naïve PC (mPC) were enrolled; all had started androgen deprivation therapy and had no visceral metastases. Bone metastases were present in 17 (77%) patients and 16 (73%) patients had affected lymph nodes. Three dose levels of UV1 were given as intradermal injections combined with GM-CSF (Leukine ). Twenty-one patients in the intention-to-treat population (95%) received conformal radiotherapy. Adverse events reported were predominantly grade 1, most frequently injection site pruritus (86.4%). Serious adverse events considered possibly related to UV1 and/or GM-CSF included anaphylactic reaction in two patients and thrombocytopenia in one patient. Immune responses against UV1 peptides were confirmed in 18/21 evaluable patients (85.7%), PSA declined to <0.5 ng/mL in 14 (64%) patients and in ten patients (45%) no evidence of persisting tumour was seen on MRI in the prostatic gland. At the end of the nine-month reporting period for the study, 17 patients had clinically stable disease. Treatment with UV1 and GM-CSF gave few adverse events and induced specific immune responses in a large proportion of patients unselected for HLA type. The intermediate dose of 0.3 mg UV1 resulted in the highest proportion of, and most rapid UV1-specific immune responses with an acceptable safety profile. These results warrant further clinical studies in mPC.
[Mh] Termos MeSH primário: Adenocarcinoma/terapia
Vacinas Anticâncer/uso terapêutico
Imunoterapia/métodos
Fragmentos de Peptídeos/uso terapêutico
Antígeno Prostático Específico/sangue
Neoplasias da Próstata/terapia
Telomerase/uso terapêutico
[Mh] Termos MeSH secundário: Adenocarcinoma/sangue
Adenocarcinoma/imunologia
Adenocarcinoma/secundário
Idoso
Neoplasias Ósseas/secundário
Vacinas Anticâncer/efeitos adversos
Vacinas Anticâncer/imunologia
Estudos de Coortes
Fator Estimulador de Colônias de Granulócitos e Macrófagos/administração & dosagem
Fator Estimulador de Colônias de Granulócitos e Macrófagos/uso terapêutico
Seres Humanos
Imunidade Ativa/imunologia
Metástase Linfática
Imagem por Ressonância Magnética
Masculino
Meia-Idade
Fragmentos de Peptídeos/efeitos adversos
Fragmentos de Peptídeos/imunologia
Antígeno Prostático Específico/imunologia
Neoplasias da Próstata/sangue
Neoplasias da Próstata/imunologia
Neoplasias da Próstata/patologia
Proteínas Recombinantes/administração & dosagem
Proteínas Recombinantes/uso terapêutico
Telomerase/efeitos adversos
Telomerase/imunologia
Vacinas de Subunidades/efeitos adversos
Vacinas de Subunidades/imunologia
Vacinas de Subunidades/uso terapêutico
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cancer Vaccines); 0 (Peptide Fragments); 0 (Recombinant Proteins); 0 (UV1 vaccine); 0 (Vaccines, Subunit); 5TAA004E22 (sargramostim); 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor); EC 2.7.7.49 (Telomerase); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170410
[St] Status:MEDLINE
[do] DOI:10.1007/s00262-017-1994-y


  5 / 3364 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27350034
[Au] Autor:Pacifico R; Davis RL
[Ad] Endereço:Department of Neuroscience, The Scripps Research Institute Florida, Jupiter, FL, USA.
[Ti] Título:Transcriptome sequencing implicates dorsal striatum-specific gene network, immune response and energy metabolism pathways in bipolar disorder.
[So] Source:Mol Psychiatry;22(3):441-449, 2017 Mar.
[Is] ISSN:1476-5578
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Bipolar disorder (BD) is a highly heritable and heterogeneous mental illness whose manifestations often include impulsive and risk-taking behavior. This particular phenotype suggests that abnormal striatal function could be involved in BD etiology, yet most transcriptomic studies of this disorder have concentrated on cortical brain regions. We believe we report the first transcriptome sequencing of the postmortem human dorsal striatum comparing bipolar (18) and control (17) subjects. Fourteen genes were detected as differentially expressed at a 5% false discovery rate, including a few immune response genes such as NLRC5, S100A12, LILRA4 and FCGBP, as well as an assortment of non-protein coding genes. Functional pathway analysis found an enrichment of upregulated genes across many immune/inflammation pathways and an enrichment of downregulated genes among oxidative phosphorylation pathways. Co-expression network analysis revealed 20 modules of highly interconnected genes; two of the modules were significantly enriched for BD susceptibility single-nucleotide polymorphisms deriving from a large genome-wide association study data set. Remarkably, the module with the highest genetic association signal for BD, which contained many genes from signaling pathways, was also enriched in markers characteristic of gene expression in dorsal striatum medium spiny neurons-unlike most other modules, which showed no such regional and neuronal specificity. These findings draw a link between BD etiology at the gene level and a specific brain region, and highlight striatal signaling pathways as potential targets for the development of novel treatments to manage BD.
[Mh] Termos MeSH primário: Transtorno Bipolar/genética
Corpo Estriado/metabolismo
Transcriptoma
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Autopsia
Transtorno Bipolar/metabolismo
Encéfalo/metabolismo
Sistema Nervoso Central/metabolismo
Metabolismo Energético/genética
Feminino
Perfilação da Expressão Gênica
Redes Reguladoras de Genes/genética
Predisposição Genética para Doença/genética
Estudo de Associação Genômica Ampla
Seres Humanos
Imunidade Ativa/genética
Masculino
Meia-Idade
Polimorfismo de Nucleotídeo Único/genética
Transcriptoma/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160629
[St] Status:MEDLINE
[do] DOI:10.1038/mp.2016.94


  6 / 3364 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27810219
[Au] Autor:Verherstraeten S; Goossens E; Valgaeren B; Pardon B; Timbermont L; Haesebrouck F; Ducatelle R; Deprez P; Van Immerseel F
[Ad] Endereço:Department of Pathology, Bacteriology and Avian Diseases, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, B-9820 Merelbeke, Belgium.
[Ti] Título:Non-toxic perfringolysin O and α-toxin derivatives as potential vaccine candidates against bovine necrohaemorrhagic enteritis.
[So] Source:Vet J;217:89-94, 2016 Nov.
[Is] ISSN:1532-2971
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Bovine necrohaemorrhagic enteritis is a fatal Clostridium perfringens type A-induced disease that is characterised by sudden death. Recently the involvement of perfringolysin O and α-toxin in the development of necrohaemorrhagic lesions in the gut of calves was suggested, and thus derivatives of these toxins are potentially suitable as vaccine antigens. In the current study, the perfringolysin O derivative PFO , alone or in combination with α-toxin derivative GST-cpa , was evaluated as possible vaccine candidate, using in vitro assays. PFO showed no haemolytic effect on horse red blood cells and no cytotoxic effect on bovine endothelial cells. Furthermore, calves immunised with PFO raised antibodies against perfringolysin O that could inhibit the perfringolysin O-associated haemolytic activity on horse red blood cells. Antisera from calves immunised with PFO had a significantly higher neutralising capacity against the cytotoxic effect of C. perfringens culture supernatant to bovine endothelial cells than serum from control calves (P <0.05). Immunisation of calves with PFO in combination with GST-cpa elicited antibodies against perfringolysin O and α-toxin and consequently inhibited both the perfringolysin O-associated haemolytic activity and the α-toxin-associated lecithinase activity in vitro. Additionally, the neutralising ability of these antisera on the cytotoxic effect of C. perfringens culture supernatant to bovine endothelial cells was significantly higher than that from calves immunised with PFO (P <0.001). In conclusion, perfringolysin O derivative PFO is an immunogenic antigen that can potentially be used to produce vaccine against bovine necrohaemorrhagic enteritis. Including α-toxin derivative GST-cpa has an additional protective effect and therefore vaccination of calves with a combination of both antigens seems even more promising.
[Mh] Termos MeSH primário: Toxinas Bacterianas/farmacologia
Vacinas Bacterianas
Proteínas de Ligação ao Cálcio/farmacologia
Doenças dos Bovinos/prevenção & controle
Infecções por Clostridium/veterinária
Enterite/veterinária
Proteínas Hemolisinas/farmacologia
Imunidade Ativa/efeitos dos fármacos
Fosfolipases Tipo C/farmacologia
[Mh] Termos MeSH secundário: Animais
Anticorpos Neutralizantes/efeitos dos fármacos
Toxinas Bacterianas/imunologia
Vacinas Bacterianas/imunologia
Vacinas Bacterianas/farmacologia
Proteínas de Ligação ao Cálcio/imunologia
Bovinos
Doenças dos Bovinos/imunologia
Doenças dos Bovinos/microbiologia
Infecções por Clostridium/imunologia
Infecções por Clostridium/microbiologia
Infecções por Clostridium/prevenção & controle
Clostridium perfringens
Células Endoteliais/efeitos dos fármacos
Enterite/imunologia
Enterite/microbiologia
Enterite/prevenção & controle
Eritrócitos/efeitos dos fármacos
Proteínas Hemolisinas/imunologia
Fosfolipases Tipo C/imunologia
Vacinas Sintéticas/imunologia
Vacinas Sintéticas/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Neutralizing); 0 (Bacterial Toxins); 0 (Bacterial Vaccines); 0 (Calcium-Binding Proteins); 0 (Hemolysin Proteins); 0 (Vaccines, Synthetic); 71329-60-7 (Clostridium perfringens theta-toxin); EC 3.1.4.- (Type C Phospholipases); EC 3.1.4.3 (alpha toxin, Clostridium perfringens)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161105
[St] Status:MEDLINE


  7 / 3364 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27760752
[Au] Autor:Brosnahan MM; Silvela EJ; Crumb J; Miller DC; Erb HN; Antczak DF
[Ad] Endereço:Baker Institute for Animal Health, Cornell University College of Veterinary Medicine, Ithaca, New York.
[Ti] Título:Ectopic Trophoblast Allografts in the Horse Resist Destruction by Secondary Immune Responses.
[So] Source:Biol Reprod;95(6):135, 2016 Dec.
[Is] ISSN:1529-7268
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Invasive trophoblast from Day 34 horse conceptuses survives in extrauterine sites in allogeneic recipients that are immunologically naive to donor major histocompatibility complex class I antigens. The ectopic trophoblast retains its in utero characteristics, including similar lifespan, physiologic effect of its secreted product (equine chorionic gonadotropin) upon the recipient's ovaries, and induction of host immune responses. Immunologic memory has not been considered previously in this experimental system. We hypothesized that primary exposure to ectopic trophoblast would affect the recipient's immune status such that the survival time of subsequent transplants would be altered. Secondary transplant lifespans could be shortened by destructive memory responses, as has been observed in ectopic trophoblast studies in rodents, or lengthened, as occurs when male skin grafts follow multiple syngeneic pregnancies in mice. Eight mares received two closely spaced trophoblast transplants. Both grafts for each recipient were obtained from conceptuses sired by the same stallion to provide consistency in histocompatibility antigen exposure. Donor stallions were major histocompatibility complex class I homozygotes. Cytotoxic antibody production was tracked to monitor recipients' immune responses to the transplants. Detection of serum equine chorionic gonadotropin was used as a proxy for transplant lifespan. There was no significant difference between the distributions of primary and secondary transplant lifespans, despite evidence of immunologic memory. These data demonstrate that secondary ectopic trophoblast transplants in horses do not experience earlier destruction or prolonged survival following immune priming of recipients. Mechanisms responsible for the eventual demise of the transplants remain unperturbed by secondary immune responses or chronic antigenic exposure.
[Mh] Termos MeSH primário: Sobrevivência de Enxerto/imunologia
Imunidade Ativa/imunologia
Trofoblastos/transplante
[Mh] Termos MeSH secundário: Aloenxertos
Animais
Feminino
Cavalos
Trofoblastos/imunologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161021
[St] Status:MEDLINE
[do] DOI:10.1095/biolreprod.115.137851


  8 / 3364 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27672225
[Au] Autor:Schwartz KL; Kwong JC; Deeks SL; Campitelli MA; Jamieson FB; Marchand-Austin A; Stukel TA; Rosella L; Daneman N; Bolotin S; Drews SJ; Rilkoff H; Crowcroft NS
[Ad] Endereço:Institute for Clinical Evaluative Sciences (Schwartz, Kwong, Campitelli, Stukel, Daneman); Institute of Health Policy, Management, and Evaluation (Schwartz, Stukel, Rosella, Daneman), University of Toronto; The Hospital for Sick Children (Schwartz); Public Health Ontario (Kwong, Deeks, Rosella, Rilk
[Ti] Título:Effectiveness of pertussis vaccination and duration of immunity.
[So] Source:CMAJ;188(16):E399-E406, 2016 Nov 01.
[Is] ISSN:1488-2329
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: A resurgence of pertussis cases among both vaccinated and unvaccinated people raises questions about vaccine effectiveness over time. Our objective was to study the effectiveness of the pertussis vaccine and characterize the effect of waning immunity and whole-cell vaccine priming. METHODS: We used the test-negative design, a nested case-control study with test-negative individuals as controls. We constructed multivariable logistic regression models to estimate odds ratios (ORs). Vaccine effectiveness was calculated as (1 - OR) × 100. We assessed waning immunity by calculating the odds of developing pertussis per year since last vaccination and evaluated the relative effectiveness of priming with acellular versus whole-cell vaccine. RESULTS: Between Dec. 7, 2009, and Mar. 31, 2013, data on 5867 individuals (486 test-positive cases and 5381 test-negative controls) were available for analysis. Adjusted vaccine effectiveness was 80% (95% confidence interval [CI] 71% to 86%) at 15-364 days, 84% (95% CI 77% to 89%) at 1-3 years, 62% (95% CI 42% to 75%) at 4-7 years and 41% (95% CI 0% to 66%) at 8 or more years since last vaccination. We observed waning immunity with the acellular vaccine, with an adjusted OR for pertussis infection of 1.27 (95% CI 1.20 to 1.34) per year since last vaccination. Acellular, versus whole-cell, vaccine priming was associated with an increased odds of pertussis (adjusted OR 2.15, 95% CI 1.30 to 3.57). INTERPRETATION: We observed high early effectiveness of the pertussis vaccine that rapidly declined as time since last vaccination surpassed 4 years, particularly with acellular vaccine priming. Considering whole-cell vaccine priming and/or boosters in pregnancy to optimize pertussis control may be prudent.
[Mh] Termos MeSH primário: Surtos de Doenças/prevenção & controle
Imunidade Ativa
Vacina contra Coqueluche/uso terapêutico
Coqueluche/epidemiologia
Coqueluche/prevenção & controle
[Mh] Termos MeSH secundário: Adolescente
Estudos de Casos e Controles
Criança
Pré-Escolar
Feminino
Seres Humanos
Esquemas de Imunização
Incidência
Lactente
Modelos Logísticos
Masculino
Análise Multivariada
Razão de Chances
Ontário/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Pertussis Vaccine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160928
[St] Status:MEDLINE


  9 / 3364 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27438603
[Au] Autor:Cao Y; Bansal GP; Merino K; Kumar N
[Ad] Endereço:Department of Tropical Medicine, School of Public Health and Tropical Medicine, and Vector-Borne Infectious Disease Research Center, Tulane University, New Orleans, Louisiana, 70112, United States of America.
[Ti] Título:Immunological Cross-Reactivity between Malaria Vaccine Target Antigen P48/45 in Plasmodium vivax and P. falciparum and Cross-Boosting of Immune Responses.
[So] Source:PLoS One;11(7):e0158212, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In general, malaria immunity has been suggested to be species specific with very little, if any, known cross-reactivity between Plasmodium vivax and P. falciparum, both of which are responsible for >90% of human malaria, and co-endemic in many countries. It is therefore believed that species-specific immunity may be needed to target different species of Plasmodium. Pfs48/45 and Pvs48/45 are well established targets in the sexual stages of the malaria parasites, and are being pursued for the development of transmission blocking vaccines. Comparison of their sequences reveals 61% and 55% identity at the DNA and protein level, respectively raising the possibility that these two target antigens might share cross-reacting epitopes. Having succeeded in expressing recombinant Pfs48/45 and Pvs48/45 proteins, we hypothesized that these proteins will not only exhibit immunological cross-reactivity but also cross-boost immune responses. Mice were immunized with purified recombinant proteins using CFA, Montanide ISA-51 and alum as adjuvants, and the sera were analyzed by ELISA, Western blotting and indirect fixed and live IFA to address the hypothesis. Our studies revealed that Pvs48/45-immune sera showed strong cross-reactivity to full length Pfs48/45 protein, and the majority of this cross reactivity was in the amino-terminal and carboxyl-terminal sub-fragments of Pfs48/45. In cross-boosting experiments Pfs48/45 and Pvs48/45 antigens were able to cross-boost each other in mouse immunization studies. Additionally we also noticed an effect of adjuvants in the overall magnitude of observed cross-reactivity. These studies may have significant implications for immunity targeting transmission of both the species of malaria parasites.
[Mh] Termos MeSH primário: Reações Cruzadas/imunologia
Vacinas Antimaláricas/imunologia
Malária Falciparum/tratamento farmacológico
Malária Vivax/tratamento farmacológico
[Mh] Termos MeSH secundário: Adjuvantes Imunológicos/uso terapêutico
Animais
Anticorpos Antiprotozoários/imunologia
Antígenos de Protozoários/imunologia
Epitopos/imunologia
Seres Humanos
Imunidade Ativa/efeitos dos fármacos
Vacinas Antimaláricas/uso terapêutico
Malária Falciparum/imunologia
Malária Vivax/imunologia
Camundongos
Plasmodium falciparum/imunologia
Plasmodium falciparum/patogenicidade
Plasmodium vivax/imunologia
Plasmodium vivax/patogenicidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adjuvants, Immunologic); 0 (Antibodies, Protozoan); 0 (Antigens, Protozoan); 0 (Epitopes); 0 (Malaria Vaccines)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170721
[Lr] Data última revisão:
170721
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160721
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0158212


  10 / 3364 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27268452
[Au] Autor:Bühler S; Hatz C
[Ad] Endereço:1 Departement Public Health, Abteilung Übertragbare Krankheiten, Institut für Epidemiologie, Biostatistik und Prävention, Universität Zürich.
[Ti] Título:[Vaccinations in patients with autoimmune diseases].
[Ti] Título:Impfungen bei Patienten mit Autoimmunerkrankungen..
[So] Source:Ther Umsch;73(5):275-80, 2016.
[Is] ISSN:0040-5930
[Cp] País de publicação:Switzerland
[La] Idioma:ger
[Ab] Resumo:The number of individuals with autoimmune diseases treated with immunosuppressive drugs is increasing steadily. The variety of immunosuppressive drugs and in particular biological therapies is also rising. The autoimmune disease itself as well as the immunosuppressive therapy increases the risk of infection in this population. Particularly the risk of vaccine-preventable infections is elevated. Thus, preventing infections by the means of vaccination is of utmost importance. The Division of Infectious Diseases of the Epidemiology, Biostatistics and Prevention Institute, University of Zurich, performed a literature search on the topic of vaccinations in patients with autoimmune diseases upon request by the Swiss Federal Commission for Vaccination Issues. Overall, data are scarce. The following main points were retrieved from the literature: Inactivated vaccines are safe, but their immunogenicity may be reduced under immunosuppressive therapy. In addition to the generally recommended basic vaccinations, specific vaccinations, such as influenza and pneumococcal vaccination are indicated in these patient groups. Live vaccines are generally contraindicated under immunosuppressive therapy due to safety concerns. However, specific exceptions apply. Furthermore, certain time intervals for the administration of live vaccines after pausing or ceasing an immunosuppressive therapy should be respected.
[Mh] Termos MeSH primário: Doenças Autoimunes/imunologia
Imunossupressores/efeitos adversos
Infecções Oportunistas/imunologia
Infecções Oportunistas/prevenção & controle
Vacinas/administração & dosagem
Vacinas/imunologia
[Mh] Termos MeSH secundário: Doenças Autoimunes/tratamento farmacológico
Seres Humanos
Imunidade Ativa/efeitos dos fármacos
Imunidade Ativa/imunologia
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Immunosuppressive Agents); 0 (Vaccines)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:160609
[Lr] Data última revisão:
160609
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160609
[St] Status:MEDLINE
[do] DOI:10.1024/0040-5930/a000792



página 1 de 337 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde